In fact, clinically, anti-VEGF therapeutics such as bevacizumab and small-molecule VEGFR inhibitors have become integral to cancer treatment by targeting this aberrant vasculature [104,105,106], and may be beneficial in psoriasis [107]. Here, KDR is linked to psoriasis.